Tumor hypoxia: a target for selective cancer therapy.
Level 5 - mechanism / opinion, no new human data
Narrative review and mechanism-based reasoning without new clinical trial data
PubMed 14662015 · doi:10.1111/j.1349-7006.2003.tb01395.x
What was done
Narrative review describing the biological characteristics of tumor hypoxia, associated treatment resistance, and molecular strategies for selectively targeting hypoxic tumor cells, including the authors' work with the hypoxia-targeting protein drug TOP3.
What was found
The abstract reports no clinical trial outcomes or quantitative comparative data. It notes that severe hypoxia (pO2 < 0.33%, 2.5 mmHg) occurs selectively in solid tumors rather than normal tissue, and identifies three main challenges to therapeutic targeting: drug delivery to poorly vascularized regions, off-target toxicity in oxygenated tissue, and the non-dividing state of severely hypoxic cells.
Why it matters
It highlights biological mechanisms and molecular approaches to overcome hypoxia-mediated resistance to radiation and chemotherapy in solid tumors.
Limits
As a narrative review, it presents expert opinion and mechanism-based preclinical discussion rather than a systematic synthesis or clinical trial evaluation.
Cited by
- supports Solid tumors are often resistant to systemic chemotherapy because they frequently grow far from blood vessels and are hypoxic, impairing drug delivery.